Abstract | BACKGROUND: OBJECTIVE: We studied the clinical and histopathologic features of a series of patients with HIV-1 protease inhibitor-associated lipodystrophy to evaluate the frequency of associated abnormalities. METHODS: The study group consisted of 14 consecutive HIV-infected patients receiving treatment with HIV-1 protease inhibitors, who experienced partial lipodystrophy. Clinical (including anthropometric data) and histopathologic findings, as well as biochemical and virologic data, were evaluated. RESULTS: CONCLUSION:
HIV-1 protease inhibitor-associated lipodystrophy represents a new entity with peculiar clinical and histopathologic features. Metabolic associated abnormalities may imply a risk of future atherogenic complications.
|
Authors | R M Pujol, P Domingo, Xavier-Matias-Guiu, E Francia, M A Sanbeat, A Alomar, G Vazquez |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 42
Issue 2 Pt 1
Pg. 193-8
(Feb 2000)
ISSN: 0190-9622 [Print] United States |
PMID | 10642672
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Anthropometry
- Body Composition
- Female
- HIV Infections
(drug therapy)
- HIV-1
- Humans
- Lipodystrophy
(chemically induced, pathology)
- Male
- Middle Aged
- Obesity
(chemically induced)
- Protease Inhibitors
(adverse effects, therapeutic use)
|